Baird analyst Catherine Ramsey Schulte lowered the firm’s price target on Exact Sciences (EXAS) to $67 from $70 and keeps an Outperform rating on the shares. The firm said they reported 3Q revenue below expectations and meaningfully lowered 2024 revenue guidance, mainly attributed to weaker Screening trends.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Exact Sciences price target lowered to $75 from $80 at Citi
- Exact Sciences price target lowered to $75 from $95 at Canaccord
- Exact Sciences Reports Strong Q3 Performance and Pipeline Advances
- Closing Bell Movers: Exact Sciences falls 30% after results, guidance cut
- Exact Sciences reports Q3 EPS (21c), consensus (21c)